Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Targeted Protein Degradation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SALL4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Target Protein | SALL4 Recombinant Protein (Full-Length & Zinc Finger Domains, including aa 1-600). High purity (>95%), Endotoxin <1EU/μg, Sequence Verified. Available in HEK293 expressed format with N-terminal His-tag. | View SALL4 Products |
| Gene Delivery | SALL4 Promise-ORF / Lentivirus – Full-length ORF for stable cell line construction, reporter assays, and degradation monitoring. CMV promoter, Puromycin selection. | View SALL4 Products |
| Benchmark Antibody | Anti-SALL4 Monoclonal Antibody – Sequence-defined, highly specific for Western Blot, Flow Cytometry, ChIP, and IF. Batch-consistent for endogenous degradation profiling. | View SALL4 Products |
| Validator | SALL4 siRNA Set (3 unique sequences) – For knockdown verification, specificity controls, and downstream pathway analysis. | View SALL4 Products |
| Mutant Panel | SALL4 C2H2 Mutant Set (Cys→Ala) – DNA-binding deficient controls for PPI-specific assays. Sequence Verified. | View SALL4 Products |
| Paralog Control | SALL1 Recombinant Protein – For selectivity screening vs. SALL family zinc fingers. | View SALL1 Products |
| Related Target A | CRBN – Essential E3 ligase partner for IMiD-induced SALL4 degradation. | View CRBN Products |
| Related Target B | IKZF1 – Counter-screening target for IMiD safety/selectivity profiling. | View IKZF1 Products |
| Related Target C | HDAC1 – NuRD complex component and SALL4 binding partner for co-IP assays. | View HDAC1 Products |
| Related Target D | CHD4 – NuRD ATPase; critical SALL4 PPI target for molecular glue development. | View CHD4 Products |
| Related Target E | BMI1 – Synergistic stemness pathway for combination studies. | View BMI1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular target engagement & cell permeability | Lentivirus-based stable ORF cell lines; high-purity full-length antigen for biochemical pulldown. |
| Paralog selectivity (SALL1 / SALL2 / SALL3 cross-reactivity) | SALL Family Protein Panel (Human/Mouse) available for counter-screening, >95% purity. Domain-specific truncations. |
| Ternary Complex Validation (SALL4-Glue-CRBN) | High purity (>95%) SALL4 zinc finger domain proteins optimized for SPR and TR-FRET assays. |
| Endogenous Degradation Monitoring | Sequence-verified monoclonal antibodies with zero cross-reactivity to SALL1/SALL2. |
| Isoform Discrimination (SALL4A vs SALL4B) | Isoform-specific Protein Variants available with N-terminal His-tag, Sequence Verified by Mass Spec. |
| PPI Disruption Validation (NuRD complex) | Cys→Ala Zinc Finger Mutants (DNA-binding null) isolate protein-protein interactions from DNA-binding effects. |
| Lack of Degradation Controls | Premade SALL4 overexpression Lentivirus to establish stable, high-signal cell lines. |
| False Positives in Binding Assays | Validated siRNA sets included for orthogonal specificity checks. |
Live SALL4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SALL4 therapeutics is intensifying, with major players shifting focus from traditional modalities to Targeted Protein Degradation (Molecular Glues and PROTACs). Originally recognized for its role in the teratogenicity of thalidomide derivatives, SALL4 has emerged as a premier oncofetal target for aggressive malignancies such as Hepatocellular Carcinoma (HCC) and Acute Myeloid Leukemia (AML). As a zinc finger transcription factor critical for cancer stem cell maintenance, SALL4 has historically resisted conventional small molecule approaches. The current R&D landscape is shifting toward targeted protein degradation and molecular glues that exploit SALL4's interaction with the NuRD complex (HDAC1/2-CHD4). As first-generation peptide inhibitors enter preclinical validation, the next wave focuses on allosteric zinc finger disruptors and isoform-selective degraders. Next-generation degraders are dialing in selectivity—either deliberately degrading SALL4 for oncology or engineering it out of the degradome for safety in autoimmune therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glue | BMS (Celgene), Monte Rosa | Solid Tumors (HCC), AML | Ternary Complex SPR (Need high-purity Recombinant Proteins) |
| PROTAC | C4 Therapeutics, Kymera | Advanced Malignancies | Degradation Kinetics (Need specific Antibodies & Lentivirus) |
| Peptide Inhibitors | Academic consortiums, early-stage biotech | Solid Tumors | Cell Penetration Assays (Need Lentivirus-stable reporter lines) |
| Zinc Finger Disruptors | Various Biotechs (Discovery) | CSC-targeted Therapy | DNA-binding Deficient Mutants (Cys→Ala) to isolate PPI inhibition |
| Isoform-Selective Degraders | Target Validation programs | Gastric Cancer, AML | SALL4A vs SALL4B Isoform-Specific Proteins for selectivity screening |
| Small Molecule (Autoimmune Safety) | Various Biotechs | Autoimmune (Safety Screen) | Selectivity Assay (Need CRBN/SALL4 vs IKZF1 panels) |
| Functional Genomics | RNAi / CRISPR screening programs | AML stem cells | Knockdown validation (Need validated SALL4 siRNA and antibodies) |
Key Genetic Variants & Mutations
Based on UniProt (Q9UJQ4) and dbSNP, the following missense variants have been documented in SALL4:
- rs6126344: Documented in UniProt as VAR_016042.
- rs6091375: Documented in UniProt as VAR_016043.
- rs74315429: Associated with DRRS (Duane-Radial Ray Syndrome); documented in UniProt as VAR_033054.
These variants are useful for designing mutant controls and understanding genotype-phenotype correlations in SALL4-related disorders.
Next-Generation Reagents: Isoform & Mutant Specific Tools
SALL4 exists as two splice variants, SALL4A and SALL4B, differing by 28 amino acids. SALL4B is predominantly oncogenic in AML, while SALL4A plays a role in germ cell development. TarMart offers isoform-specific recombinant proteins and corresponding lentiviral constructs to support selective degrader development. Additionally, the Cys→Ala Zinc Finger Mutant Set provides a critical control for distinguishing DNA-binding inhibition from protein-protein interaction disruption.